Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	TP53	Synonyms	BCC7, BMFS5, LFS1, P53, TRP53	Type of gene	protein-coding
Chromosome	17	Map location	17p13.1	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	tumor protein p53

GTO ID	GTC0010
Trial ID	NCT00044993
Disease	Breast Cancer
Altered gene	P53
Therapeutic/Target gene	Therapeutic gene
Therapy	Gene transfer
Treatment	INGN-201\|Advexin\|AdV5.CMV-p53
Co-treatment	docetaxel\|doxorubicin hydrochloride\|conventional surgery\|neoadjuvant therapy
Phase	Phase2
Recruitment status	Completed
Title	Phase II, Single Arm, Single Institution Clinical Trial of Docetaxel and Doxorubicin in Combination With Local Administration of INGN 201 (Ad5CMV-p53) in Locally Advanced Breast Cancer (LABC)
Year	2002
Country	United States
Company sponsor	Introgen Therapeutics
Other ID(s)	INTROGEN-201-010\|CDR0000256223\|MDA-ID-00008

Vector information

Vector	adenovirus
Construct	Ad5-CMV-p53
Vector type	replication-impaired adenovirus serotype 5 (Ad5) vector
Transgene/Inserted gene	human wild-type p53 gene
Regulatory element	a cytomegalovirus (CMV) promoter
Viral genome modification	The E1 region of the parental adenovirus DNA is deleted.

Clinical Result

Cohort 1

Administration route	intralesional injection
Dosage	2.5E12 vp
Pts	12
Age	Adult, Older_Adult
Outcome	12/12(PR)
Adverse reactions	1/12(episode of febrile neutropenia); 1/12(episode of hypoglycemia); 1/12(hypotension); 3/12(skin inflammation; 2/12(fever); 1/12(fatigue); 1/12(myalgia); 1/12(breast pain); 1/12(anemia); 1/12(weight loss)
References	PMID: 16874816

Relationship Graph

Overview of Knowledge Graph